17:07 , Jan 26, 2018 |  BC Week In Review  |  Company News

Novartis to begin ex-U.S. compassionate use program for Arzerra

Genmab A/S (CSE:GEN; Pink:GMXAY) said partner Novartis AG (NYSE:NVS; SIX:NOVN) will begin offering Arzerra ofatumumab to patients outside the U.S. through compassionate use programs. Genmab said that over the past five years, additional CLL drugs...
05:14 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Roche's Ocrevus receives EU approval for MS

The European Commission approved Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat the relapsing and primary progressive forms of multiple sclerosis (PPMS). Roche said Ocrevus is the first and only disease-modifying drug for PPMS approved...
20:35 , Jan 12, 2018 |  BC Extra  |  Company News

Roche's Ocrevus receives EU approval for MS

Roche (SIX:ROG; OTCQX:RHHBY) said the European Commission approved Ocrevus ocrelizumab to treat the relapsing and primary progressive forms of multiple sclerosis (PPMS). Roche said Ocrevus is the first and only disease-modifying drug for PPMS approved...
04:00 , Oct 28, 2017 |  BioCentury  |  Product Development

Chinks in the armor

Even with slowing revenues tied largely to a single product and a dearth of launches, Wall Street darling Celgene Corp. had been on an extended tear, growing its share price in excess of 300% since...
18:56 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

TG Therapeutics modifies Phase IIb trial of TG-1101

TG Therapeutics Inc. (NASDAQ:TGTX) said an independent DSMB recommended discontinuation of the TGR-1202 (umbralisib) monotherapy arm of the Phase IIb UNITY-NHL trial in the diffuse large B cell lymphoma (DLBCL) cohort after a pre-planned interim...
18:56 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

TG Therapeutics modifies Phase IIb trial of TGR-1202

TG Therapeutics Inc. (NASDAQ:TGTX) said an independent DSMB recommended discontinuation of the TGR-1202 (umbralisib) monotherapy arm of the Phase IIb UNITY-NHL trial in the diffuse large B cell lymphoma (DLBCL) cohort after a pre-planned interim...
20:16 , Oct 20, 2017 |  BioCentury  |  Finance

Early opportunity

Preliminary data from ongoing studies of lead candidate Hu5F9-G4 enabled Forty Seven Inc. to raise a $75 million series B round sooner than expected. The new funds will allow Forty Seven to launch and complete...
20:47 , Jul 7, 2017 |  BC Week In Review  |  Clinical News

DSMB recommends continuation of TG's ublituximab Phase III trial

TG Therapeutics Inc. (NASDAQ:TGTX) said an independent DSMB recommended the company cease enrollment in the 2 monotherapy arms of the Phase III UNITY-CLL trial evaluating ublituximab (TG-1101, TGTX-1101) and TGR-1202 to treat chronic lymphocytic leukemia...
20:45 , Jul 7, 2017 |  BC Week In Review  |  Clinical News

DSMB recommends continuation of TG's TGR-1202 Phase III trial

TG Therapeutics Inc. (NASDAQ:TGTX) said an independent DSMB recommended the company cease enrollment in the 2 monotherapy arms of the Phase III UNITY-CLL trial evaluating ublituximab ( TG-1101 , TGTX-1101) and TGR-1202 to treat chronic...
22:10 , Mar 14, 2017 |  BC Extra  |  Company News

FDA panel to discuss binimetinib, subcutaneous rituximab

FDA’s Oncologic Drugs Advisory Committee will meet on March 29 to discuss a BLA from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) for subcutaneous rituximab , as well as an NDA from Array BioPharma...